Business Trip
by Greg Kubin & Matias Serebrinsky
Is this your podcast?Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 1 chart position in 1 market.
By chart position
- 🇪🇸ES · Mental Health#1871K to 10K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
500 to 5K🎙 Weekly cadence·66 episodes·Last published 5d ago - Monthly Reach
Unique listeners across all episodes (30 days)
1K to 10K🇪🇸100% - Active Followers
Loyal subscribers who consistently listen
300 to 3K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 11 epsHosts
Recent guests
Recent episodes
Why Most Drugs Fail, and Why Virtual Tissue Models Beat Virtual Cell Models
Aug 27, 2026
48m 50s
Virtual Mitochondrial Models and the Case for Engineering Humans with Mariëlle van Kooten
Jul 9, 2026
24m 23s
Brain Organoids: from Space to AI with Alysson Muotri
May 14, 2026
34m 18s
How Gilgamesh Landed a $1.2B AbbVie Deal in Psychedelics
Mar 25, 2026
26m 25s
Inside Philanthropy’s Role in Mental & Brain Health
Jan 27, 2026
42m 02s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 8/27/26 |  Why Most Drugs Fail, and Why Virtual Tissue Models Beat Virtual Cell Models | Naren Tallapragada (co-founder of Tessel) joins to talk about the industry of modeling biology. While the field races to build virtual cell models, his team builds virtual tissue models, betting that predicting what an organ actually does matters more than predicting what genes a cell expresses. The goal: not just whether a drug works, but who it works for. In this episode, we discuss: Why 90% of drugs fail in clinical trials, and why neuro and Alzheimer's failure rates are even worseThe mul... | 48m 50s | ||||||
| 7/9/26 | mitochondriahuman engineering+3 | Mariëlle van Kooten | Powerhouse Biology | — | mitochondriaengineering+4 | — | 24m 23s | ||
| 5/14/26 | brain organoidsspace research+3 | Alysson R. Muotri | UC San Diego | International Space Station | brain organoidsspace+4 | — | 34m 18s | ||
| 3/25/26 | psychedelic medicinespharmaceutical partnerships+3 | Jonathan Sporn | Gilgamesh PharmaAbbVie | — | psychedelicsGilgamesh Pharma+5 | — | 26m 25s | ||
| 1/27/26 | mental health philanthropyfunding trends+3 | Alyson NiemanSabrina Gracias+1 | Mindful PhilanthropyOrtus Foundation+1 | — | mental healthphilanthropy+3 | — | 42m 02s | ||
| 12/19/25 | IbogainePTSD+4 | Rick Perry | StanfordReal Summit | — | IbogaineRick Perry+5 | — | 39m 50s | ||
| 11/24/25 | brain targetingblood brain barrier+3 | James Gorman | Wyss Institute | — | brain shuttlesdrug transport+3 | — | 48m 31s | ||
| 10/16/25 | AI in therapybehavioral health+3 | Luis Voloch | Jimini HealthImmunai | — | AItherapy+3 | — | 38m 09s | ||
| 9/23/25 | psychiatryneuromodulation+5 | Rob Malenka | pharmabiotech+2 | — | psychiatryneuromodulation+8 | — | 1h 32m 43s | ||
| 8/21/25 | Alzheimer's treatmentcell therapy+4 | Brendon Boot | Skin2NeuronHarvard+2 | — | Alzheimer'sneurons+5 | — | 54m 18s | ||
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 7/22/25 | mitochondriahealth+3 | Natalie Yivgi-Ohana | MinoviaThe Hebrew University+1 | — | mitochondriahealth+5 | — | 51m 30s | ||
| 6/26/25 | genetics of sleepnatural short sleepers+3 | Ying-Hui Fu | UCSF | — | sleep geneticsshort sleepers+3 | — | 33m 11s | ||
| 4/17/25 |  What's wrong with US healthcare and how startups can fix it, with Justin Mares | Matias and Greg interview Justin Mares, co-founder of TrueMed and Kettle & Fire on current US healthcare and how startups have the opportunity to change the system. In this episode, we discuss: How the US system profits from chronic illnessFixing the food system, environmental toxins, pharma incentives & moreOpportunities for founders building in brain and body health.Contrarian ideas Justin is investing in todayCredits: Created by Greg Kubin and Matias Serebrinsky Host: Matias Sere... | 37m 39s | ||||||
| 1/30/25 |  Temporal Interference: The Future of Brain Stimulation with Nir Grossman | Matias and Greg interview Dr. Nir Grossman, one of the world’s leading researchers in neurotechnology. Nir is a lecturer in the Department of Brain Sciences at Imperial College London and a founding fellow of the UK Dementia Research Institute. In this episode, we discuss: What is temporal interference (TI), a non-invasive stimulation methodA comparison of TI with deep brain stimulation (DBS)How physics plays a crucial role in neuroscience innovationTranslating TI academic research to c... | 22m 07s | ||||||
| 12/26/24 |  The State of Autism Part 2 with James Adams of Gut-Brain-Axis Therapeutics Inc. | Greg and Matias interview Dr. James Adams, professor and autism researcher at Arizona State University and President of Gut-Brain-Axis Therapeutics, on groundbreaking research in autism. In this episode, we discuss: The latest advancements in microbiome therapy for autismHow the gut-brain axis is shaping new therapeutic approachesThe role of nutritional interventions in supporting individuals with autismEnvironmental factors and toxins influencing autism developmentCredits: Created by Greg K... | 40m 03s | ||||||
| 12/12/24 |  The State of Autism Part 1 with Elizabeth Horn of 2m Foundation | Matias interviews Elizabeth Horn, founder of the 2m Foundation, on the current state of autism and what can we do about it. In this episode, we discuss: The rising prevalence of autism and its impact on societyHow 2m Foundation is funding research and solutionsEnvironmental and biological factors contributing to autismPhilanthropy and venture capital through the Autism Impact FundCredits: Created by Greg Kubin and Matias Serebrinsky Host: Matias Serebrinsky & Greg Kubin Produced by Jonat... | 37m 46s | ||||||
| 11/14/24 |  Genetic Medicine for Brain Health with Dana Watt of Breakout Ventures | Matias and Greg interview Dana Watt, a Partner at Breakout Ventures, about genetic medicine for brain and mental health. In this episode, we discuss: How genetic therapies work: addressing underlying causes, not just symptomsThe opportunities and challenges for genetic therapies for brain healthExploring effective delivery of genetic payloadsCommercial viability and insurance considerationsCredits: Created by Greg Kubin and Matias Serebrinsky Host: Matias Serebrinsky & Greg Kubin Produc... | 44m 17s | ||||||
| 9/5/24 |  Transcranial Focused Ultrasound for Mental Health with Jay Sanguinetti of Sanmai | Greg and Matias interview Jay Sanguinetti, founder of Sanmai Technologies, a startup using transcranial focused ultrasound for the treatment of mental health conditions. Jay has a background in academia, having worked at the University of Arizona and started the SEMA Lab (Science Enhanced Mindful Awareness). In this episode, we discuss: The science behind transcranial focused ultrasound and its therapeutic potential for mental healthThe risks and considerations involved in using focused... | 59m 47s | ||||||
| 8/23/24 |  Navigating FDA clinical trials in Neurotech with Tim Marjenin | Greg and Matias interview Tim Marjenin, a regulatory consultant at MCRA with 16 years of experience at the FDA, to discuss the regulatory landscape for neurotechnology devices. Tim provides insights into the FDA approval process for neurotech devices, drawing from his extensive experience on the FDA's Neurostimulation-Neurology Devices Team. The episode explores the evolving field of neurotechnology and its regulatory challenges. In this episode, we discuss: Different regulatory pathways for ... | 41m 02s | ||||||
| 7/18/24 |  Environmental Toxins and Mental Health with Gurdane Bhutani | Greg and Matias interview Gurdane Bhutani, an investor at MBX Ventures, to discuss the impact of environmental toxins on health and the field of exposomics. Gurdane is an expert in environmental health, with a background in Epidemiology and Environmental Health Sciences. He provided insights into the pervasive nature of environmental toxins and their implications for public health. This episode also has a guest appearance from Bruce Blumberg, a Professor of Developmental and Cell Biology at U... | 49m 17s | ||||||
| 6/21/24 |  FDA advisors say no to MDMA. What’s the impact? With Josh Hardman | Greg and Matias interview Josh Hardman, founder and editor of Psychedelic Alpha, to discuss the recent FDA advisory committee meeting on Lykos Therapeutics’ MDMA-assisted therapy for PTSD. Josh is a leading writer covering the intersection of psychedelics and business. He provided live reporting and analysis of the AdComm meeting. In this episode, we discuss: The FDA advisory committee process and its implications for drug approvalsFunctional unblinding and expectancy effects in psychedelic c... | 56m 55s | ||||||
| 5/7/24 |  Investing in New Frontiers of Mental Health (Live at SXSW) | Software, hardware, and biotechnology are playing an increasingly transformative role in our mental health and wellness. Join us as we discuss what investors look for in these new companies and how they separate what’s real — and what’s near-term — from what’s hype. We’ll explore AI-powered tools for mental health, the new area of “enerceuticals” (energy replacing the “pharma”), psychedelics, and why what’s in your gut is so important to your mental state. Hear from investors who have a wide ... | 50m 33s | ||||||
| 4/9/24 |  Comparing Psychedelic Compounds in Therapy (Live Panel at Battery SF) | Matias hosted a panel at The Battery SF with renowned psychedelics experts, Nolan Williams, Allison Feduccia, Matt Baggott. Nolan is a Stanford professor currently researching ibogaine among other areas in psychiatry and radiology, and he's a founder of TMS company Magnus Medical. Allison is the founder of Psychedelic Support, a platform providing psychedelic education, community and a provider directory. And Matt is founder and CEO of Tactogen, a biotech company developing compounds similar... | 1h 01m 53s | ||||||
| 3/14/24 |  What Payers Want with Lili Brillstein | Matias interviews Lili Brillstein about how to work collaboratively with healthcare payers (the ones that reimburse for medical expenses). Lili is a pioneer in the field, having previously led one of the largest bundled payment initiatives at Horizon Blue Cross Blue Shield. She currently is the founder of her own advisory firm, BCollaborative, where she helps startups and providers develop value propositions that resonate with payers and create models that can be successfully administered.&n... | 48m 20s | ||||||
| 2/22/24 |  Decoding the Brain with Ed Boyden | Greg and Matias interview Ed Boyden about neuroscience frontiers and its applications to mental health. Ed is a pioneer in understanding the fundamental mechanisms of the brain. He runs a lab at MIT for Synthetic Neurobiology and is a professor across the departments of neurotechnology, biological engineering, and cognitive science at MIT’s McGovern Institute for Brain Research. His inventions include optogenetic tools and expansion microscopy. He is co-founder of Cognito Therapeutics, Elemi... | 50m 37s | ||||||
Showing 25 of 69
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Chart history for Business Trip
Peaked at #187 in Spain, currently #187 in Spain.
| Market | Genre | Peak | Current | Trend |
|---|---|---|---|---|
| Spain | — | #187 | #187 | — |
Chart Positions
1 placement across 1 market.
Chart Positions
1 placement across 1 market.